AUTH/3644/5/22 and AUTH/3694/10/22 - Complainant v Croma Pharma

Excessive hospitality in relation to a Letybo launch symposium

  • Received
    10 May 2022
  • Case number
    AUTH/3644/5/22 and AUTH/3694/10/22
  • Applicable Code year
  • Completed
    08 June 2023
  • Breach Clause(s)
  • Sanctions applied
    Undertaking received
  • Additional sanctions
  • Appeal
    No appeal

Case Summary

This case was in relation to a Croma Pharma Letybo (botulinum toxin type A) launch symposium held in Monaco. 

The Panel ruled the following breaches of the 2021 Code because it considered that the impression created by the arrangements of the symposium was such that hospitality, including the venue, did not appear to be secondary to the main purpose of the event, and this was compounded by the poor impression created by the signage: 

Breach of Clause 5.1

Failing to maintain high standards

Breach of Clause 10.1

Providing inappropriate hospitality

For the poor impression created by the arrangements, noting that hospitality provided, in particular at international meetings, attracted public scrutiny and noting that the relevant supplementary information included matters of excessive hospitality, Croma Pharma was, on balance, ruled in breach of the following Clause of the 2021 Code: 

Breach of Clause 2

Bringing discredit upon, and reducing confidence in, the pharmaceutical industry


This summary is not intended to be read in isolation.
            For full details, please see the full case report below.